查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
化疗引起的周围神经病变治疗的全球市场-2022-2029
市场调查报告书
商品编码
1140674

化疗引起的周围神经病变治疗的全球市场-2022-2029

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

研发的持续增长将在预测期内继续支持市场增长。

在化疗引起的周围神经病变市场上运营的公司正在不断开发有效的药物和药物来管理化疗。体内的癌细胞强调给予小剂量的治疗周围神经病变的药物。因此，展望未来，全球化疗引起的周围神经病变市场的主要市场参与者正在加大对肿瘤学研究的投资。例如，2021 年 12 月，Paxman KTP 创造了一种新设备来防止化疗副作用 CIPN。哈德斯菲尔德大学和 Paxman 合作开发了一种医疗冷却系统，以预防化疗引起的周围神经病变 (CIPN)。 CIPN 会导致接受化疗的患者四肢进行性且通常是不可逆的疼痛和敏感，从而导致治疗延误和停药。

此外，与研究机构的合作正在推动全球市场的增长。哈佛健康评论提供有关神经系统疾病管理和治疗的相关信号。许多化疗诱导的周围神经病变市场公司预计将与哈佛研究奖学金合作，并从合作研究中受益。从化疗引起的周围神经病变的角度来看，哈佛医学院的见解已经使许多公司、研究单位和泌尿系统疾病受益。

但是，与治疗相关的副作用可能会阻碍全球化疗引起的周围神经病变市场。

地理渗透率

在整个预测期内，北美主导着全球市场。

该研究按地区分析了全球市场中化疗引起的周围神经病变市场，包括北美、欧洲、亚太地区、南美、中东和非洲。

北美在全球化疗引起的周围神经病变市场占据主导地位，预计在预测期内将保持其地位。美国为 2022 年北美化疗引起的周围神经病变治疗市场做出了贡献。各种癌症的发病率和患病率的增加增加了对抗癌药物的需求。与末期使用的其他治疗选择（例如免疫治疗和靶向治疗）相比，这种增长是由于癌症治疗早期阶段的化疗。

预计在预测期内，亚太地区化疗引起的周围神经病变市场将显着增长。这种增长可归因于该地区医疗保健基础设施的快速发展和宣传活动的增加。此外，印度、中国、新加坡和马来西亚等新兴国家医疗旅游的增长估计也对全球化疗引起的周围神经病变市场产生积极影响。

竞争格局

化疗引起的周围神经病变市场是一个竞争激烈的市场。化疗引起的周围神经病变治疗的主要参与者为全球市场的增长做出了贡献，包括 Regency Pharmaceuticals、Nemus Bioscience Inc、PledPharma、Immune Pharmace Inc.、DermaXon LLC。领先公司正在为全球化疗引起的周围神经病变市场的增长采用新产品发布和扩张战略。 2022年3月，旭化成製药宣布在日本和美国用于预防化疗引起的周围神经病变（CIPN）的ART-123（通用名：thrombomodulin alfa，日本商品名：recomodulin Note）将成为全球首个1 期试验。宣布开始在患有以下疾病的患者中进行药物管理试验该试验将与 Asahi Kasei Corporation 的全资子公司 Veloxis Pharmaceuticals, Inc. 联合进行。 2021年9月， Novaled 收购了 Metys Pharmaceuticals ，以扩大其在慢性疼痛中的非鸦片类药物候选药物的管道。此次收购旨在为患者提供有效且耐受性良好的药物，同时满足对非成瘾疗法的迫切需求。

COVID-19 的影响将对全球化疗引起的周围神经病变市场产生负面影响。

COVID-19 的爆发无疑影响了全球化疗引起的周围神经病变市场。封锁迫使诊断出新的癌症病例，因此在 COVID-19 流行期间降低了化疗引起的周围神经病变治疗的采用率。因此，化疗引起的周围神经病变市场预计在 2020 年将大幅下降。

内容

第 1 章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按产品划分的市场细分
  • 按应用划分的市场细分
  • 最终用户的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
  • 促进因素
    • 癌症发病率增加
    • 提高新兴国家的意识
  • 抑制因素
    • 治疗的副作用
  • 商机
  • 影响分析

第 5 章行业分析

  • 波特五力分析
  • 供应链分析
  • 价值链分析
  • PEST 分析
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求
  • 专利趋势

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品分类

  • 钙通道 A2-delta 配体
  • 抗忧郁药
  • 鸦片类药物
  • 其他

第 8 章按应用程序

  • 白金配方
  • 紫杉烷
  • 长春花生物碱
  • 其他

第 9 章最终用户

  • 医院和诊所
  • 癌症中心

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 竞争场景
  • 市场定位/市场份额分析
  • 併购分析

第 12 章公司简介

  • Asahi Kasei Pharma Corp
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Regency Pharmaceuticals
  • MAKScientific LLC
  • Metys Pharmaceuticals AG
  • Nemus Bioscience Inc
  • PledPharma
  • Sova Pharmaceuticals Inc
  • DermaXon LLC
  • Immune Pharmaceuticals Inc.
  • Solasia Pharma K.K.

第 13 章 DataM

简介目录
Product Code: DMHCIT3008

Market Overview

Chemotherapy-Induced Peripheral Neuropathy Treatment Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 5 % during the forecast period (2022-2029).

Chemotherapy-induced peripheral neuropathy is a serious clinical problem induced by several chemotherapeutics drugs or cytotoxic drugs such as platinum, taxanes, and vinca alkaloids eribulin, epothilones, and bortezomib. These drugs cause different pathological problems to the neurons. The pathological problems lead to the degeneration of peripheral sensory and motor nerves and cause patients to present with sensory disturbances, balance problems, or weakness. The technological advancement in the treatment and diagnosis of cancer and the rising incidence of chemotherapy-induced peripheral neuropathy is expected to propel the market growth. Moreover, the increasing demand for cost-efficient therapeutics in emerging regions is an opportunity for market growth.

Market Dynamics: Continuous rise in R&D will continue supporting the growth of the market during the forecast period.

The companies operating in the chemotherapy-induced peripheral neuropathy market are constantly developing efficient drugs and medications to manage chemotherapy. Cancerous cells in the body make it critical to administer minor doses of drugs for peripheral neuropathy. Henceforth, the key market players in the global chemotherapy-induced peripheral neuropathy market are ramping up their oncological research investments. For instance, in December 2021, Paxman KTP created a new device to prevent chemotherapy side-effect CIPN. University of Huddersfield and Paxman partnered to develop a medical cooling system to prevent Chemotherapy-induced peripheral neuropathy (CIPN). CIPN causes progressive and often irreversible pain or sensitivity in the hands and feet of patients undergoing chemotherapy leading to delays and discontinuation of treatment.

Also, collaboration with research institutes is driving the growth of the global market. Harvard Health Reviews have been offering relevant signals for the management and treatment of neuropathy. Numerous chemotherapy-induced peripheral neuropathy market companies are expected to collaborate with Harvard's research fraternity to reap the benefits of collaborative research. The Harvard Medical School insights have already helped numerous companies, research units, and chemotherapy-induced peripheral neuropathy'stand nature and uropathy.

However, the adverse effect associated with the treatment may hamper the global chemotherapy-induced peripheral neuropathy treatment market.

Market Segmentation: The antidepressants segment accounted for the highest share in global chemotherapy-induced peripheral neuropathy treatment market.

Antidepressant contributes the major share of the chemotherapy-induced peripheral neuropathy treatment market. It has a clinically meaningful effect on chemotherapy-induced peripheral neuropathy. Adjunct treatment options for chemotherapy-induced peripheral neuropathy include a topical analgesic, a tricyclic antidepressant, an anticonvulsant, or an SNRI. Therefore, realizing the potential benefits of chemotherapy-induced peripheral neuropathy as an antidepressant will drive market growth during the forecast period.

The chemotherapy-induced peripheral neuropathy treatment market has been classified into platinum agents, taxanes, vinca alkaloids, and others based on the application. The Platinum Agents segment held a significant market share in the global chemotherapy-induced peripheral neuropathy treatment market in the forecast period. The major application of platinum agents is the chemotherapy-induced peripheral neuropathy treatment market. Platinum agents (carboplatin, cisplatin, and oxaliplatin) are a class of chemotherapy agents with a wide range of activity against several solid tumors. Toxicity to the peripheral nervous system is the key dose-reducing toxicity of a few platinum drugs of clinical interest. Among the platinum compounds, cisplatin is considered the most neurotoxic, inducing mainly sensory neuropathy of the upper and lower extremities.

Geographical Penetration: North America dominated the global market throughout the forecast period.

Based on geography, the study analyzes the chemotherapy-induced peripheral neuropathy treatment market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America dominated the global chemotherapy-induced peripheral neuropathy treatment market and is expected to retain its position during the forecast period. The U.S. contributed over xx % to the North American chemotherapy-induced peripheral neuropathy treatment market in 2022. The increase in the incidence and prevalence rate of different cancer has led to a rise in demand for cancer drugs. This growth is due to chemotherapy in earlier cancer treatment stages compared to other therapy options such as immunological therapy drugs and targeted therapy drugs used in the late stage.

The Asia Pacific is estimated to grow considerably in the chemotherapy-induced peripheral neuropathy treatment market during the forecast period. This growth can be accredited to the rapidly developing healthcare infrastructure and rising awareness programs in this region. Further, growing medical tourism in developing countries such as India, China, Singapore, and Malaysia is also estimated to positively youth the global chemotherapy-induced peripheral neuropathy treatment market.

Competitive Landscape:

The chemotherapy-induced peripheral neuropathy treatment market is highly competitive. The key chemotherapy-induced peripheral neuropathy treatment players contributing to the global market's growth market include Regency Pharmaceuticals, Nemus Bioscience Inc, PledPharma, Immune PharmaceIncnc., and DermaXon LLC. The major players are adopting new product launches and expansion strategies for global growth in the chemotherapy-induced peripheral neuropathy treatment market. In March 2022, Asahi Kasei Pharma announced that a drug administration study began for the first patient in the Japan-US international phase 1 study of ART-123 (generic name: thrombomodulin alfa; marketed as Recomodulin Injection in Japan) for the prevention of chemotherapy-induced peripheral neuropathy (CIPN). This study is performed jointly with Veloxis Pharmaceuticals, Inc., a wholly-owned subsidiary of Asahi Kasei Corp. In September 2021, Novaremed acquired Metys Pharmaceuticals to expand its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications. This acquisition aims to deliver effective and well-tolerated medications to patients while simultaneously addressing the urgent need for non-addictive treatments.

COVID-19 Impact: Negative impact on the global chemotherapy-induced peripheral neuropathy treatment market.

The outbreak of COVID-19 has certainly impacted the global chemotherapy-induced peripheral neuropathy treatment market, as the lockdown has compelled the diagnosis of new cancer cases, which in turn has derailed the adoption rate of chemotherapy-induced peripheral neuropathy treatment amidst the COVID-19 pandemic. Therefore, the chemotherapy-induced peripheral neuropathy treatment market is expected to foresee a considerable decline in 2020.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by End-Users
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Increasing incidence of cancer
    • 4.2.2. Rising awareness in emerging economies
  • 4.3. Restraints:
    • 4.3.1. Side-effects of treatment
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
  • 7.3. Market Attractiveness Index, By Product Segment
    • 7.3.1. Calcium Channel A2-delta Ligands*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Antidepressants
    • 7.3.3. Opioids
    • 7.3.4. Others

8. By Application

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 8.3. Market Attractiveness Index, By Application Segment
    • 8.3.1. Platinum Agents*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Taxanes
    • 8.3.3. Vinca Alkaloids
    • 8.3.4. Others

9. By End-Users

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users Segment
  • 9.3. Market Attractiveness Index, By End-Users Segment
    • 9.3.1. Hospitals & Clinics*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Cancer Centers

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. The U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. The U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. The Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Asahi Kasei Pharma Corp*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Regency Pharmaceuticals
  • 12.3. MAKScientific LLC
  • 12.4. Metys Pharmaceuticals AG
  • 12.5. Nemus Bioscience Inc
  • 12.6. PledPharma
  • 12.7. Sova Pharmaceuticals Inc
  • 12.8. DermaXon LLC
  • 12.9. Immune Pharmaceuticals Inc.
  • 12.10. Solasia Pharma K.K.

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us